

# Lizza E L Hendriks

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4081466/publications.pdf>

Version: 2024-02-01

119  
papers

3,910  
citations

147801

31  
h-index

144013

57  
g-index

119  
all docs

119  
docs citations

119  
times ranked

5646  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperhydration with cisplatin does not influence pemetrexed exposure. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 871-876.	2.4	2
2	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	2.8	7
3	Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART. <i>Lancet Oncology</i> , The, 2022, 23, 8-9.	10.7	3
4	Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 170, 95-101.	0.6	2
5	Radiotherapy for small cell lung cancer in current clinical practice guidelines. <i>Journal of the National Cancer Center</i> , 2022, , .	7.4	2
6	Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?. <i>European Journal of Cancer</i> , 2022, 167, 149-151.	2.8	2
7	Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 499-502.	1.1	1
8	Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 147-165.	3.8	12
9	Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. <i>Lung Cancer</i> , 2022, 169, 94-101.	2.0	6
10	Automated detection and segmentation of non-small cell lung cancer computed tomography images. <i>Nature Communications</i> , 2022, 13, .	12.8	44
11	Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. <i>Oncologist</i> , 2021, 26, e1347-e1358.	3.7	28
12	Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology. <i>Radiotherapy and Oncology</i> , 2021, 155, 269-277.	0.6	19
13	Durvalumab, with or without tremelimumab, plus platinum+etoposide versus platinum+etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65.	10.7	356
14	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	7.0	76
15	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 145, 221-229.	2.8	42
16	Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 368-370.	1.1	8
17	Lung Cancer in the Netherlands. <i>Journal of Thoracic Oncology</i> , 2021, 16, 355-365.	1.1	11
18	Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?. <i>Cancers</i> , 2021, 13, 2132.	3.7	5

#	ARTICLE	IF	CITATIONS
19	Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. <i>Cells</i> , 2021, 10, 930.	4.1	50
20	The prognostic value of weight and body composition changes in patients with non-small cell lung cancer treated with nivolumab. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 657-664.	7.3	18
21	Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. <i>Lung Cancer</i> , 2021, 155, 163-169.	2.0	23
22	Trends and variations in treatment of stage III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands. <i>Lung Cancer</i> , 2021, 155, 103-113.	2.0	14
23	Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	0
24	Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?. <i>Translational Lung Cancer Research</i> , 2021, 10, 2868-2875.	2.8	1
25	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2970-2987.	2.8	11
26	Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review. <i>Cancers</i> , 2021, 13, 3144.	3.7	5
27	How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3486-3502.	2.8	8
28	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	2.8	24
29	Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2321-2323.	1.6	9
30	Toxicity of pemetrexed during renal impairment explained—Implications for safe treatment. <i>International Journal of Cancer</i> , 2021, 149, 1576-1584.	5.1	9
31	Targeted therapies for unresectable stage III non-small cell lung cancer. <i>Mediastinum</i> , 2021, 5, 22-22.	1.1	7
32	Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103460.	4.4	3
33	Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?. <i>European Respiratory Journal</i> , 2021, 58, 2101637.	6.7	2
34	Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. <i>Cancers</i> , 2021, 13, 6259.	3.7	17
35	Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?. <i>Lung Cancer</i> , 2020, 139, 216-218.	2.0	5
36	Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. <i>Lung Cancer</i> , 2020, 140, 107-112.	2.0	21

#	ARTICLE	IF	CITATIONS
37	Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 383-391.	1.1	58
38	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). <i>Cancers</i> , 2020, 12, 2827.	3.7	35
39	Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study. <i>BMJ Open</i> , 2020, 10, e036492.	1.9	5
40	EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. <i>Cancer Treatment Reviews</i> , 2020, 90, 102105.	7.7	80
41	Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis. <i>Frontiers in Oncology</i> , 2020, 10, 577696.	2.8	15
42	Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 509297.	2.8	3
43	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184.	2.8	65
44	First-line immune-chemotherapy combination for squamous NSCLC is already a reality. <i>Translational Lung Cancer Research</i> , 2020, 9, 819-823.	2.8	1
45	<p>Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6885-6896.	2.0	1
46	Palliative Care for Cancer Patients During the COVID-19 Pandemic, With Special Focus on Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1405.	2.8	18
47	Combination treatments with immunotherapy in brain metastases patients. <i>Future Oncology</i> , 2020, 16, 1691-1705.	2.4	2
48	Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 88, 102025.	7.7	14
49	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	2.6	29
50	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. <i>Frontiers in Medicine</i> , 2020, 7, 90.	2.6	31
51	Combination of Immunotherapy and Radiotherapyâ€”The Next Magic Step in the Management of Lung Cancer?. <i>Journal of Thoracic Oncology</i> , 2020, 15, 166-169.	1.1	10
52	Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 890.	2.8	5
53	Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm. <i>European Respiratory Journal</i> , 2020, 55, 1901907.	6.7	27
54	Current challenges in the management of nonsmall cell lung cancer brain metastases. <i>European Respiratory Journal</i> , 2020, 55, 1901686.	6.7	2

#	ARTICLE	IF	CITATIONS
55	The Emerging Role of Radiomics in COPD and Lung Cancer. <i>Respiration</i> , 2020, 99, 99-107.	2.6	33
56	Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2599-2617.	2.8	10
57	ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases. <i>European Oncology and Haematology</i> , 2020, 16, 18.	0.0	3
58	Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2053-2061.	1.1	52
59	Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1513-1527.	1.1	83
60	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1400-1407.	1.1	23
61	Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	1.1	189
62	Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. <i>European Journal of Cancer</i> , 2019, 123, 28-35.	2.8	19
63	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	2.8	33
64	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. <i>Lung Cancer</i> , 2019, 136, 145-147.	2.0	17
65	Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?. <i>Lung Cancer</i> , 2019, 129, 95-97.	2.0	3
66	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 116, 182-189.	2.8	36
67	Imaging of regional ventilation: Is CT ventilation imaging the answer? A systematic review of the validation data. <i>Radiotherapy and Oncology</i> , 2019, 137, 175-185.	0.6	20
68	Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study. <i>European Journal of Cancer</i> , 2019, 115, 88-96.	2.8	21
69	Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?. <i>Lancet Respiratory Medicine</i> , 2019, 7, 291-292.	10.7	1
70	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1244-1254.	1.1	178
71	Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study. <i>Radiotherapy and Oncology</i> , 2019, 135, 141-146.	0.6	21
72	The electronic nose: emerging biomarkers in lung cancer diagnostics. <i>Breathe</i> , 2019, 15, e135-e141.	1.3	15

#	ARTICLE	IF	CITATIONS
73	Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1701-1703.	1.1	6
74	Prospects of targeted and immune therapies in SCLC. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 151-167.	2.4	16
75	Responding to the challenges of international collaborations between the east and the west – report of the first JCOG–EORTC symposium and a perspective from young JCOG and EORTC investigators. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 96-99.	1.3	2
76	Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2015-2015.	1.6	0
77	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46.	2.8	69
78	Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. <i>European Journal of Cancer</i> , 2018, 91, 92-98.	2.8	30
79	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	1.6	747
80	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 647-660.	2.8	66
81	Brain imaging in early stage non-small cell lung cancer: still a controversial topic?. <i>Journal of Thoracic Disease</i> , 2018, 10, S2168-S2171.	1.4	10
82	Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 511.	2.8	4
83	P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, S466-S467.	1.1	1
84	Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO). <i>Annals of Oncology</i> , 2018, 29, viii511.	1.2	4
85	External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 249-256.	0.6	8
86	Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450). <i>Journal of Thoracic Oncology</i> , 2018, 13, 1958-1961.	1.1	72
87	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018, 71, 47-58.	7.7	37
88	Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 121, 76-81.	2.0	38
89	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. <i>Cancer Treatment Reviews</i> , 2018, 68, 69-79.	7.7	51
90	Invasive Aspergillosis Mimicking Metastatic Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 188.	2.8	14

#	ARTICLE	IF	CITATIONS
91	New windows open for immunotherapy in lung cancer. <i>Nature</i> , 2018, 558, 376-377.	27.8	38
92	Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions. <i>Frontiers in Oncology</i> , 2018, 8, 154.	2.8	40
93	Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 6-11.	2.0	39
94	The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation. <i>Frontiers in Oncology</i> , 2018, 8, 241.	2.8	18
95	What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer. <i>Lung Cancer</i> , 2018, 123, 112-115.	2.0	2
96	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9003-9003.	1.6	16
97	Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9066-9066.	1.6	0
98	Assessment of clinical, radiological and radiomic predictive factors of bevacizumab efficacy in brain metastases radionecrosis treatment.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14003-e14003.	1.6	0
99	Assessment of efficacy and safety of bevacizumab in the treatment of brain metastases radionecrosis: A retrospective cohort analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14014-e14014.	1.6	0
100	Screening for Brain Metastases in Resectable Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, e21.	1.1	1
101	Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4251-4258.	7.0	62
102	Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. <i>Oncologist</i> , 2017, 22, 222-235.	3.7	25
103	Heat shock protein antagonists in early stage clinical trials for NSCLC. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 541-550.	4.1	50
104	Management of stage I and II nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1600764.	6.7	56
105	The Current Role of Whole Brain Radiation Therapy in Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1467-1477.	1.1	18
106	Non-small cell lung cancer with a single metastasis, the new stage M1b; does the site matter?. <i>Cancer Treatment and Research Communications</i> , 2017, 13, 1-2.	1.7	0
107	Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?. <i>Lung Cancer</i> , 2016, 101, 68-75.	2.0	11
108	Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. <i>Radiotherapy and Oncology</i> , 2016, 121, 26-31.	0.6	46

#	ARTICLE	IF	CITATIONS
109	Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non- <sup>3</sup> Small Cell Lung Cancer and Bone Metastases: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2016, 11, 155-173.	1.1	41
110	Proposals for the M-descriptors of the Eight TNM Classification for Non- <sup>3</sup> Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e42-e43.	1.1	2
111	An Uncommon Presentation of Brain Metastases in a Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1655-1656.	1.1	2
112	Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review. <i>Cancer Treatment Reviews</i> , 2015, 41, 634-645.	7.7	33
113	Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. <i>European Journal of Cancer</i> , 2015, 51, 2534-2544.	2.8	50
114	Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 249-254.	2.0	30
115	Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases. <i>Acta Oncol<sup>3</sup>gica</i> , 2014, 53, 945-951.	1.8	16
116	EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?. <i>Lung Cancer</i> , 2014, 84, 86-91.	2.0	102
117	Retrospective analysis of type of <i>KRAS</i> mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8061-8061.	1.6	1
118	Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?. <i>Lung Cancer</i> , 2013, 80, 293-297.	2.0	22
119	Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3